Samuel M. Silver, MD, PhD, and Margaret A. Tempero, MD, on Multidisciplinary Management of Pancreatic Cancer
2015 NCCN Annual ConferenceSamuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed for hematologic malignancies that have activity in pancreatic cancer, vaccines, neoadjuvant treatment, and the need to focus on activated RAS.
Related Videos
Robert W. Carlson, MD, and William J. Gradishar, MD, on Optimizing Treatment of HER2-Positive Breast Cancer
Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of...
Wui-Jin Koh, MD, on Making NCCN Guidelines Relevant Around the Globe
Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with dif...
Melinda Telli, MD, on Evolving Treatment Strategies for Triple-Negative Breast Cancer
Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.
Thomas A. D’Amico, MD, on Diagnosis and Treatment of NSCLC Using Minimally Invasive Techniques
Thomas A. D’Amico, MD, of Duke Cancer Institute, discusses the superior efficacy of thoracoscopic lobectomy. This minimally invasive procedure is used in only 50% of lung cancer su...
Robert W. Carlson, MD, and John A. Gentile, Jr, on Milestones of NCCN
Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early ...
